LFG
NTLA icon

Larson Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Larson Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.74K Buy
292
+196
+204% +$2.5K ﹤0.01% 2736
2025
Q4 		$863 Sell
96
-34
-26% -$468 ﹤0.01% 2995
2025
Q3 		$2.25K Buy
130
+61
+88% +$751 ﹤0.01% 2657
2025
Q2 		$647 Buy
69
+39
+130% +$320 ﹤0.01% 2783
2025
Q1 		$213 Hold
30
– – ﹤0.01% 2785
2024
Q4 		$350 Sell
30
-32
-52% -$499 ﹤0.01% 2294
2024
Q3 		$1.27K Sell
62
-138
-69% -$3.18K ﹤0.01% 1940
2024
Q2 		$4.48K Buy
200
+170
+567% +$4.05K ﹤0.01% 1470
2024
Q1 		$825 Buy
30
+20
+200% +$556 ﹤0.01% 1485
2023
Q4 		$305 Buy
+10
New +$287 ﹤0.01% 1621

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return